MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.730
+0.140
+3.05%
Opening 11:17 08/12 EDT
OPEN
4.590
PREV CLOSE
4.590
HIGH
4.900
LOW
4.550
VOLUME
309.06K
TURNOVER
--
52 WEEK HIGH
7.78
52 WEEK LOW
1.900
MARKET CAP
133.77M
P/E (TTM)
-1.6960
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADMS stock price target is 9.31 with a high estimate of 20.00 and a low estimate of 3.000.

EPS

ADMS News

More
Adamas Pharma EPS beats by $0.24, beats on revenue
Adamas Pharma (NASDAQ:ADMS): Q2 GAAP EPS of -$0.37 beats by $0.24. Revenue of $18.79M (+48.1% Y/Y) beats by $3.48M. Cash, cash equivalents and available-fo
seekingalpha · 5d ago
Adamas Reports Second Quarter 2020 Financial Results
Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019 Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, I
GlobeNewswire · 5d ago
Will Adamas Pharmaceuticals (ADMS) Report Negative Earnings Next Week? What You Should Know
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
SPPI, TESS, CRMD and ADMS among after-hours movers
Seeking Alpha · 07/27 21:45
Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ manageme
GlobeNewswire · 07/23 20:02
Adamas announces post-hoc data supporting benefit of Gocovri in Parkinson's
Adamas Pharmaceuticals (ADMS +4.5%) announces new post-hoc Phase 3 data showing that Gocovri decreased dyskinesia and OFF time (periods where levodopa ther
seekingalpha · 07/15 20:39
Adamas Highlights Presentation Of New Post-Hoc Phase 3 Data Analysis For GOCOVRI Ini Parkinson's Disease At 2020 American Academy Of Neurology (AAN) Science Highlights Platform
EMERYVILLE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by
Benzinga · 07/15 12:03
Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinson’s disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform
EMERYVILLE, Calif., July 15, 2020 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to.
GlobeNewswire · 07/15 12:00

Industry

Biotechnology & Medical Research
+0.19%
Pharmaceuticals & Medical Research
+1.45%

Hot Stocks

Symbol
Price
%Change

About ADMS

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
More

Webull offers kinds of Adamas Pharmaceuticals Inc stock information, including NASDAQ:ADMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMS stock methods without spending real money on the virtual paper trading platform.